



2100 Pennsylvania Avenue, NW
Washington, DC 20037-3213
T 202.293.7060
F 202.293.7860
www.sughrue.com

Date December 18, 2009

To Examiner Blessing Fubara

Of U.S. Patent and Trademark Office

Fax (571) 273-0594

From John T. Callahan / Hui C. Wauters

Subject **Outline for Examiner Interview
U.S. Patent Application No. 10/501,393**

Our Ref Q82517

Pages **2** (including cover sheet)

Please call attention to problems with this transmission by return fax or telephone. Thank you.

THE INFORMATION CONTAINED IN THIS COMMUNICATION IS CONFIDENTIAL, MAY BE ATTORNEY-CLIENT PRIVILEGED, AND IS INTENDED ONLY FOR THE USE OF THE ADDRESSEE. UNAUTHORIZED USE, DISCLOSURE OR COPYING IS STRICTLY PROHIBITED AND MAY BE UNLAWFUL. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US.

Examiner Blessing Fubara
Art Unit 1618
USPTO
Fax: 571-273-0594

Re: **Outline for Examiner Interview**
U.S. Patent Application No.: 10/501,393
Inventor: Andrew Lennard LEWIS
Assignee: BIOCOMPATIBLES UK LIMITED
Sughrue Ref: Q82517

Dear Examiner Fubara:

The following is an outline for the telephone interview scheduled for Tuesday, December 22, 2009, at 11 am, which is for your consideration and for discussion purposes only.

1. Claim 34 might be amended to recite that "R⁴¹ and R⁴² are independently selected from the group consisting of hydrogen, C₁-C₂₀ straight, branched and cyclic alkyl, aryl, aralkyl, C₁-C₂₀ hydroxy-alkyl, and acyloxy-C₁-C₂₀-alkyl, C₃-C₈ cycloalkyl, C₃-C₈ hydroxy-cycloalkyl and acyloxy-C₃-C₈-cycloalkyl."

2. Claim 34 might be further amended to recite that "OR⁴³ is selected from the group consisting of an alkoxy of from 1 to 20 carbon atoms, an aryloxy and a heterocycloxy, having that is biologically active substituent."